% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Wen:284381,
      author       = {P. Y. Wen and M. van den Bent and G. Youssef and T. F.
                      Cloughesy and B. M. Ellingson and M. Weller and E. Galanis
                      and D. P. Barboriak and J. de Groot and M. R. Gilbert and R.
                      Huang and A. B. Lassman and M. Mehta and A. M. Molinaro and
                      M. Preusser and R. Rahman and L. K. Shankar and R. Stupp and
                      J. E. Villanueva-Meyer and W. Wick$^*$ and D. R. Macdonald
                      and D. A. Reardon and M. A. Vogelbaum and S. M. Chang},
      title        = {{RANO} 2.0: {U}pdate to the {R}esponse {A}ssessment in
                      {N}euro-{O}ncology {C}riteria for {H}igh- and {L}ow-{G}rade
                      {G}liomas in {A}dults.},
      journal      = {Journal of clinical oncology},
      volume       = {41},
      number       = {33},
      issn         = {0732-183X},
      address      = {Alexandria, Va.},
      publisher    = {American Society of Clinical Oncology},
      reportid     = {DKFZ-2023-01975},
      pages        = {5187-5199},
      year         = {2023},
      note         = {2023 Nov 20;41(33):5187-5199},
      abstract     = {The Response Assessment in Neuro-Oncology (RANO) criteria
                      for high-grade gliomas (RANO-HGG) and low-grade gliomas
                      (RANO-LGG) were developed to improve reliability of response
                      assessment in glioma trials. Over time, some limitations of
                      these criteria were identified, and challenges emerged
                      regarding integrating features of the modified RANO (mRANO)
                      or the immunotherapy RANO (iRANO) criteria.Informed by data
                      from studies evaluating the different criteria, updates to
                      the RANO criteria are proposed (RANO 2.0).We recommend a
                      standard set of criteria for both high- and low-grade
                      gliomas, to be used for all trials regardless of the
                      treatment modalities being evaluated. In the newly diagnosed
                      setting, the postradiotherapy magnetic resonance imaging
                      (MRI), rather than the postsurgical MRI, will be used as the
                      baseline for comparison with subsequent scans. Since the
                      incidence of pseudoprogression is high in the 12 weeks after
                      radiotherapy, continuation of treatment and confirmation of
                      progression during this period with a repeat MRI, or
                      histopathologic evidence of unequivocal recurrent tumor, are
                      required to define tumor progression. However, confirmation
                      scans are not mandatory after this period nor for the
                      evaluation of treatment for recurrent tumors. For treatments
                      with a high likelihood of pseudoprogression, mandatory
                      confirmation of progression with a repeat MRI is highly
                      recommended. The primary measurement remains the maximum
                      cross-sectional area of tumor (two-dimensional) but
                      volumetric measurements are an option. For IDH wild-type
                      glioblastoma, the nonenhancing disease will no longer be
                      evaluated except when assessing response to antiangiogenic
                      agents. In IDH-mutated tumors with a significant
                      nonenhancing component, clinical trials may require
                      evaluating both the enhancing and nonenhancing tumor
                      components for response assessment.The revised RANO 2.0
                      criteria refine response assessment in gliomas.},
      cin          = {B320 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B320-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37774317},
      doi          = {10.1200/JCO.23.01059},
      url          = {https://inrepo02.dkfz.de/record/284381},
}